Biotech firm ImmunoPrecise's FY25 revenue misses estimates

Reuters07-29

Biotech firm ImmunoPrecise's FY25 revenue misses estimates

Overview

ImmunoPrecise FY25 revenue was C$24.5 mln, missing analyst expectations
Record Q4 revenue of C$7.0 mln, driven by BioStrand segment growth
Q4 Adjusted EBITDA loss improved to C$0.3 mln, reflecting operational efficiency

Outlook

Company anticipates completing divestiture of Dutch subsidiary soon
ImmunoPrecise to focus on AI-based product development
Company expects strategic steps to enhance core capabilities
ImmunoPrecise aims to streamline operations with strategic priorities

Result Drivers

BIOSTRAND GROWTH - BioStrand segment grew over 180% in FY25, contributing to improved gross margins
OPERATIONAL EFFICIENCY - Q4 Adjusted EBITDA loss improved due to enhanced operational efficiency
GROSS MARGIN IMPROVEMENT - Gross margin rose to 64% in Q4 FY25, driven by high-margin BioStrand revenues

Key Details

Metric	Beat/Miss	Actual	Consensus Estimate
FY Revenue	Miss	C$24.50 mln	C$25.40 mln (2 Analysts)
FY Net Income		-C$30.20 mln
FY Gross Profit		C$13.50 mln

Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 2 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"
The average consensus recommendation for the pharmaceuticals peer group is "buy"
Wall Street's median 12-month price target for Immunoprecise Antibodies Ltd is $4.00, about 49.5% above its July 28 closing price of $2.02

Press Release: ID:nBw4tGpmKa

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2555505946?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-07-29 20:39","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2555505946","market":"us","top_or_hot":-1,"title":"Biotech firm ImmunoPrecise's FY25 revenue misses estimates","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>Biotech firm ImmunoPrecise's FY25 revenue misses estimates</title></head><body><p><span>Overview</span></p><ul><li><p>ImmunoPrecise FY25 revenue was C$24.5 mln, missing analyst expectations</p></li><li><p>Record Q4 revenue of C$7.0 mln, driven by BioStrand segment growth</p></li><li><p>Q4 Adjusted EBITDA loss improved to C$0.3 mln, reflecting operational efficiency</p></li></ul><p><span>Outlook</span></p><ul><li><p>Company anticipates completing divestiture of Dutch subsidiary soon</p></li><li><p>ImmunoPrecise to focus on AI-based product development</p></li><li><p>Company expects strategic steps to enhance core capabilities</p></li><li><p>ImmunoPrecise aims to streamline operations with strategic priorities</p></li></ul><p><span>Result Drivers</span></p><ul><li><p>BIOSTRAND GROWTH - BioStrand segment grew over 180% in FY25, contributing to improved gross margins</p></li><li><p>OPERATIONAL EFFICIENCY - Q4 Adjusted EBITDA loss improved due to enhanced operational efficiency</p></li><li><p>GROSS MARGIN IMPROVEMENT - Gross margin rose to 64% in Q4 FY25, driven by high-margin BioStrand revenues</p></li></ul><p><span>Key Details</span></p><table><tbody><tr><td><p><span>Metric</span></p></td><td><p><span>Beat/Miss</span></p></td><td><p><span>Actual</span></p></td><td><p><span>Consensus Estimate</span></p></td></tr><tr><td><p>FY Revenue</p></td><td><p>Miss</p></td><td><p>C$24.50 mln</p></td><td><p>C$25.40 mln (2 Analysts)</p></td></tr><tr><td><p>FY Net Income</p></td><td></td><td><p>-C$30.20 mln</p></td><td></td></tr><tr><td><p>FY Gross Profit</p></td><td></td><td><p>C$13.50 mln</p></td><td></td></tr></tbody></table><p><span>Analyst Coverage</span></p><ul><li><p>The current average analyst rating on the shares is \"buy\" and the breakdown of recommendations is 2 \"strong buy\" or \"buy\", no \"hold\" and no \"sell\" or \"strong sell\"</p></li><li><p>The average consensus recommendation for the pharmaceuticals peer group is \"buy\"</p></li><li><p><a href=\"https://laohu8.com/S/WSCO\">Wall Street</a>'s median 12-month price target for <a href=\"https://laohu8.com/S/IPA\">Immunoprecise Antibodies Ltd</a> is $4.00, about 49.5% above its July 28 closing price of $2.02</p></li></ul><p>Press Release: <span>ID:nBw4tGpmKa</span></p><p>(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Biotech firm ImmunoPrecise's FY25 revenue misses estimates</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBiotech firm ImmunoPrecise's FY25 revenue misses estimates\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-07-29 20:39</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>Biotech firm ImmunoPrecise's FY25 revenue misses estimates</title></head><body><p><span>Overview</span></p><ul><li><p>ImmunoPrecise FY25 revenue was C$24.5 mln, missing analyst expectations</p></li><li><p>Record Q4 revenue of C$7.0 mln, driven by BioStrand segment growth</p></li><li><p>Q4 Adjusted EBITDA loss improved to C$0.3 mln, reflecting operational efficiency</p></li></ul><p><span>Outlook</span></p><ul><li><p>Company anticipates completing divestiture of Dutch subsidiary soon</p></li><li><p>ImmunoPrecise to focus on AI-based product development</p></li><li><p>Company expects strategic steps to enhance core capabilities</p></li><li><p>ImmunoPrecise aims to streamline operations with strategic priorities</p></li></ul><p><span>Result Drivers</span></p><ul><li><p>BIOSTRAND GROWTH - BioStrand segment grew over 180% in FY25, contributing to improved gross margins</p></li><li><p>OPERATIONAL EFFICIENCY - Q4 Adjusted EBITDA loss improved due to enhanced operational efficiency</p></li><li><p>GROSS MARGIN IMPROVEMENT - Gross margin rose to 64% in Q4 FY25, driven by high-margin BioStrand revenues</p></li></ul><p><span>Key Details</span></p><table><tbody><tr><td><p><span>Metric</span></p></td><td><p><span>Beat/Miss</span></p></td><td><p><span>Actual</span></p></td><td><p><span>Consensus Estimate</span></p></td></tr><tr><td><p>FY Revenue</p></td><td><p>Miss</p></td><td><p>C$24.50 mln</p></td><td><p>C$25.40 mln (2 Analysts)</p></td></tr><tr><td><p>FY Net Income</p></td><td></td><td><p>-C$30.20 mln</p></td><td></td></tr><tr><td><p>FY Gross Profit</p></td><td></td><td><p>C$13.50 mln</p></td><td></td></tr></tbody></table><p><span>Analyst Coverage</span></p><ul><li><p>The current average analyst rating on the shares is \"buy\" and the breakdown of recommendations is 2 \"strong buy\" or \"buy\", no \"hold\" and no \"sell\" or \"strong sell\"</p></li><li><p>The average consensus recommendation for the pharmaceuticals peer group is \"buy\"</p></li><li><p><a href=\"https://laohu8.com/S/WSCO\">Wall Street</a>'s median 12-month price target for <a href=\"https://laohu8.com/S/IPA\">Immunoprecise Antibodies Ltd</a> is $4.00, about 49.5% above its July 28 closing price of $2.02</p></li></ul><p>Press Release: <span>ID:nBw4tGpmKa</span></p><p>(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":null,"symbol_name":null,"start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250729:nPLXBB5B9C:1","article_id":"2555505946","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2555505946","pubTimestamp":1753792753,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Biotech firm ImmunoPrecise's FY25 revenue misses estimatesOverviewImmunoPrecise FY25 revenue was C$24.5 mln, missing analyst expectationsRecord Q4 revenue of C$7.0 mln, driven by BioStrand segment gro","collect":0,"end_time":0,"defaultTopTitle":"","property":["earning"],"viewcount":null,"language":"en","relate_stocks":{},"translate_title":"生物技术公司Immunoprecise 2025财年收入未达预期","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"IPA":0.9},"content_text":"Biotech firm ImmunoPrecise's FY25 revenue misses estimatesOverviewImmunoPrecise FY25 revenue was C$24.5 mln, missing analyst expectationsRecord Q4 revenue of C$7.0 mln, driven by BioStrand segment growthQ4 Adjusted EBITDA loss improved to C$0.3 mln, reflecting operational efficiencyOutlookCompany anticipates completing divestiture of Dutch subsidiary soonImmunoPrecise to focus on AI-based product developmentCompany expects strategic steps to enhance core capabilitiesImmunoPrecise aims to streamline operations with strategic prioritiesResult DriversBIOSTRAND GROWTH - BioStrand segment grew over 180% in FY25, contributing to improved gross marginsOPERATIONAL EFFICIENCY - Q4 Adjusted EBITDA loss improved due to enhanced operational efficiencyGROSS MARGIN IMPROVEMENT - Gross margin rose to 64% in Q4 FY25, driven by high-margin BioStrand revenuesKey DetailsMetricBeat/MissActualConsensus EstimateFY RevenueMissC$24.50 mlnC$25.40 mln (2 Analysts)FY Net Income-C$30.20 mlnFY Gross ProfitC$13.50 mlnAnalyst CoverageThe current average analyst rating on the shares is \"buy\" and the breakdown of recommendations is 2 \"strong buy\" or \"buy\", no \"hold\" and no \"sell\" or \"strong sell\"The average consensus recommendation for the pharmaceuticals peer group is \"buy\"Wall Street's median 12-month price target for Immunoprecise Antibodies Ltd is $4.00, about 49.5% above its July 28 closing price of $2.02Press Release: ID:nBw4tGpmKa(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.11","shortVersion":"4.35.11","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2555505946","isCrawlerRequest":true}